FDA Approves a Triple Therapy for Type 2 Diabetes in One Tablet
Feb 4, 2020
Editor: Steve Freed, R.PH., CDE
Author: George McConnell, PharmD. Candidate, LECOM School of Pharmacy
A few days ago, the FDA approved Trijardy XR. A combination of three, previously approved medications, Trijardy XR combines empagliflozin, linagliptin, and metformin hydrochloride extended-release. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, linagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin hydrochloride, a biguanide, are all agents used to treat type 2 diabetes. The advantage of combining these agents is that they each have a different mechanism of action, so they lower blood glucose in different ways....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.